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Difference in Outcome 
between Types of KRAS 
Mutation May Point 
toward Difference in 
Tumor Biology
To the Editor: 
With interest we read the article 
by Nadal et al.1 entitled “KRAS-G12C 
mutation is associated with poor 
outcome in surgically resected lung 
adenocarcinoma”.
The authors retrospectively studied 
a group of 179 patients with surgically 
resected adenocarcinoma of the lung with 
known KRAS mutational status. The aim 
of this study was to investigate the effects, 
if any, of KRAS mutant subtypes on sur-
vival probabilities. Here, patients with any 
KRAS mutation had significant poorer sur-
vival compared with patients with KRAS 
wild type. In particular, patients with a 
G12C mutation had worse outcome com-
pared with other types of mutation.
We would like to comment on 
this article. First, the authors report that 
patients with a G12C KRAS mutation 
have a poorer prognosis compared with 
other types of KRAS mutations, which is 
illustrated in Figure 1. The authors also 
refer to a univariate analysis presented in 
Table 3 (p.1518). However, the univariate 
analysis provides a comparison between 
G12C KRAS mutation and wild type, but 
not G12C and non-G12C KRAS muta-
tions. A difference in prognosis between 
types of KRAS mutation could possibly 
point toward differences in tumor biol-
ogy. This is relevant data and we would 
like to invite the author to present the 
data of a multivariate analysis compar-
ing G12C and other types of KRAS 
mutations. Furthermore, it is interest-
ing to know how many patients had an 
EGFR mutation among the patients with 
KRAS wild type. This group of patient 
is known to a have favorable prognosis2 
and can provide a relevant bias.
We agree that the prognostic value 
of KRAS mutation is a controversial topic. 
As discussed in the article, two large stud-
ies on KRAS mutational status in resected 
non–small-cell lung carcinoma did not 
found a prognostic value for KRAS muta-
tion or types of mutation.3,4 Over the past 
decade, almost a dozen studies investi-
gated the same question in non–small-
cell lung carcinoma with conflicting 
results. The study by Nadal et al. should 
therefore be interpreted carefully, despite 
methodological differences. Nonetheless, 
the data on KRAS addiction is interesting 
and we hope that future studies will point 
out the clinical relevance.
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